THE SHORT ANSWER
Does CVS Caremark Cover Zepbound?
October 2026: Zepbound Is Preferred Again
Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize). From July 1, 2025 to September 30, 2026, Zepbound (tirzepatide) was nonpreferred or excluded on some of CVS Caremark's most common commercial template formularies (reported as the Standard, Advanced Control, and Value formularies), not all, with Wegovy preferred.[1] Employers and plans can customize their formulary, so some plans may still exclude Zepbound: check your own plan (CVS Health announcement).
CVS Caremark also keeps Wegovy (semaglutide) as a preferred GLP-1 for weight loss. If your CVS Caremark-managed plan still excludes Zepbound, you may need to:
- Switch to Wegovy (also a preferred option on CVS Caremark's template formularies)
- Request a formulary exception if you can't tolerate Wegovy or it's not effective
- Check whether your specific employer plan uses CVS Caremark's standard formulary or a customized one
- Pay out-of-pocket or use Lilly's savings programs
Important: CVS Caremark is a pharmacy benefit manager (PBM), not an insurance company. Your employer or insurer contracts with CVS Caremark to manage prescription benefits. Some employers may have negotiated continued Zepbound coverage—always verify with your specific plan.
Scale of impact: According to GoodRx research, over 100 million Americans lack commercial insurance coverage for Zepbound as of 2026—up sharply from prior years.[14]
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get starteddenied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
"I found Honest Care online and was very impressed with the letter... the appeal worked!"
"My Appeal was approved the next day. Thank you Honest Care!"
WHY THIS MATTERS FOR YOUR COVERAGE
Understanding CVS Caremark as a PBM
CVS Caremark is a pharmacy benefit manager (PBM)—a middleman between your insurance company and pharmacies. Understanding this distinction is key to navigating your Zepbound coverage:
| Role | What They Do | Examples |
|---|---|---|
| Insurance Company | Sets overall benefits, pays claims, decides what's covered | Blue Cross, Aetna, UnitedHealthcare, Cigna |
| Employer (Self-Funded) | May customize drug benefits beyond standard formulary | Large corporations, government entities |
| PBM (CVS Caremark) | Manages formulary, processes Rx claims, negotiates drug prices | CVS Caremark, Express Scripts, OptumRx |
Why Does This Matter?
A CVS Caremark formulary change doesn't affect every member the same way:
- Employers can opt out — Self-funded employers can negotiate to keep Zepbound on their specific formulary
- Your insurer may override — Some insurers contract with CVS Caremark but require different formulary rules
- Exceptions are possible — Even excluded drugs can be covered via formulary exception requests
How to Check Your Specific Coverage
Your ID card tells you who to call. Look for "Rx Bin" or "Pharmacy" on your card—if it shows CVS Caremark, your prescription benefits are managed by them. But your employer or insurer may have negotiated different terms.
Call both: (1) your HR department and (2) the number on your card.
2025 COVERAGE CHANGES
CVS Caremark Formulary & Tier Status
Here's the status of GLP-1 medications on CVS Caremark's standard formularies (Zepbound row updated October 2026; other rows as of July 2025):
| Medication | Indication | Standard Formulary | Tier |
|---|---|---|---|
| Zepbound (tirzepatide) | Weight loss | Preferred again since Oct 1, 2026 (nonpreferred or excluded on some formularies Jul 2025 – Sep 2026) | Check your plan |
| Wegovy (semaglutide) | Weight loss | Preferred | Tier 2/3 |
| Mounjaro (tirzepatide) | Type 2 diabetes | Covered | Tier 2 |
| Ozempic (semaglutide) | Type 2 diabetes | Covered | Tier 2 |
| Saxenda (liraglutide) | Weight loss | Limited | Tier 3 |
Which CVS Caremark Formularies Made Zepbound Nonpreferred or Excluded It?
These are the formulary types reported to have made Zepbound nonpreferred or excluded it from July 1, 2025, until it was added back as an additional preferred option on October 1, 2026 (plan sponsors could customize, and exceptions were possible):[2]
- Standard Control Formulary — Most common employer formulary
- Advanced Control Formulary — More restrictive formulary with lower premiums
- Value Formulary — Cost-focused formulary used by smaller employers
Class Action Lawsuits: What Patients Should Know
In September 2025, two class action lawsuits were filed against CVS Caremark:[3][17]
- Larkin v. CVS Caremark (Sept. 3, 2025 – S.D.N.Y., Case No. 1:25-cv-07307)
- Hamburger v. CVS Caremark (Sept. 4, 2025 – D.D.C.)
Key allegations from the complaint:
- ERISA violations: CVS allegedly prioritized its own rebate profits over patient health outcomes
- Market power: CVS Caremark controls 27% of all U.S. pharmacy claims
- Financial motive: Novo Nordisk (Wegovy) allegedly pays larger rebates than Eli Lilly (Zepbound)
Patient impact examples from court filings: One plaintiff (Dennis Larkin) lost 104.2 lbs on Zepbound and saw his sleep apnea resolve; another (Danielle Gosline) lost over 70 lbs. Both now face losing access.
CVS Caremark has called the lawsuits "without merit."[18]
Call Script: Checking Your Coverage
Call Script for CVS Caremark
"Hi, I'm calling to check coverage for a prescription medication. My member ID is [NUMBER]. I need to know:
- Is Zepbound (tirzepatide) covered on my specific plan's formulary for weight management?
- If not on formulary, does my employer's plan allow formulary exceptions?
- What documentation is needed for a formulary exception request?
- What's the process to request an exception if my doctor believes Zepbound is medically necessary?
- Can I get this coverage determination in writing?"
Pro tip: Call your HR department first. They may know whether your employer follows CVS Caremark's standard formulary (Zepbound preferred since October 1, 2026) or customized it, or has a special arrangement for GLP-1 coverage.
CVS CAREMARK CRITERIA
Formulary Exception Requirements
If your plan still excludes Zepbound (a customized formulary may), you'll need to request a formulary exception. Typical requirements:
- Prior drug trials — Some plans may require trying another drug first; check your plan’s criteria
- BMI ≥30, or ≥27 with a comorbidity (diabetes, hypertension, sleep apnea)
- Letter of Medical Necessity from your doctor explaining why Zepbound is specifically needed
For complete prior auth preparation, see our Zepbound prior authorization guide →
YOUR OPTIONS
What to Do If Denied
Good News: Most Appeals Succeed
Appeals work: for Medicare Advantage, over 80% of prior auth appeals succeed[4]; for commercial insurance like CVS Caremark plans, success rates are at least 65%+ when properly documented. Yet fewer than 1 in 10 patients ever file an appeal—those who do have a real chance of getting coverage.
Common CVS Caremark Denial Reasons
- "Not on formulary" — Plan still excludes Zepbound (a common denial on some Caremark template formularies from July 2025 to September 2026)
- "Step therapy not completed" — Plan requires trying another drug first
- "Does not meet criteria" — BMI or comorbidity requirements not documented
- "Insufficient documentation" — Missing records of prior treatments
What to Do:
Get the Denial in Writing
Request a written denial letter with the specific reason for denial.
Check Your Plan's Criteria
Some plans may require trying another drug first; check your plan’s criteria. If your plan does require a trial of another drug (such as Wegovy) and it doesn't work or causes side effects, that documentation supports a Zepbound exception.
Request a Formulary Exception
If your plan excludes Zepbound, your doctor submits documentation of medical necessity for Zepbound, including any prior drug trials.
File Your Appeal
You generally have 180 days to file an internal appeal (check your denial letter). Need help? Use Honest Care to build your appeal →
Alternative Pathways
New: $200/Month Copay Option (Select Plans)
Some CVS Caremark plans now offer a $200/month copay option for GLP-1 weight loss medications where no coverage existed before. Compare it with self-pay through LillyDirect ($299–$449/month; TrumpRx.gov lists the same LillyDirect prices). Ask your HR department if your plan offers this option.[20]
Have an Employer Plan? Talk to HR
Self-funded employers can opt out of CVS Caremark's standard formulary. Ask HR if your plan has special GLP-1 coverage arrangements.
Open Enrollment
During open enrollment, evaluate plans using different PBMs (Express Scripts, OptumRx) that may still cover Zepbound.
For complete appeal strategies, see our Zepbound appeals guide →
CVS CAREMARK ZEPBOUND COVERAGE
Frequently Asked Questions
Yes, on its commercial template formularies again: Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize). From July 1, 2025 to September 30, 2026, Zepbound was nonpreferred or excluded on some of CVS Caremark's most common commercial template formularies. Employers and plans can customize their formulary, so some may still exclude Zepbound—check with your HR department and CVS Caremark directly to verify your specific plan's coverage.
CVS Caremark says the change was made to provide "wider access to effective weight management treatment" by standardizing on Wegovy. However, two class action lawsuits allege the real reason is financial: Novo Nordisk (Wegovy's maker) allegedly pays CVS Caremark larger rebates than Eli Lilly (Zepbound's maker). The plaintiffs claim CVS violated ERISA by prioritizing its own profits over patient health outcomes. CVS has called these lawsuits "without merit."
Yes, if your plan still excludes Zepbound. Some plans may require trying another drug first; check your plan’s criteria. To get a formulary exception for Zepbound, you typically need to show: (1) any prior drug trials your plan requires (for example, that another drug didn't work or caused intolerable side effects), (2) you meet BMI criteria (≥30 or ≥27 with comorbidity), and (3) your doctor submits a Letter of Medical Necessity explaining why Zepbound is specifically needed for your case. Eli Lilly provides free templates at zepbound.lilly.com/access to help with this process.
CVS Caremark is a pharmacy benefit manager (PBM), not an insurer. CVS Caremark controls about 27% of all U.S. pharmacy claims, making them one of the "Big Three" PBMs alongside Express Scripts and OptumRx. Your employer or insurance company contracts with CVS Caremark to manage prescription drug benefits. This means: your insurer sets overall coverage rules, your employer may customize those rules (if self-funded), and CVS Caremark manages the formulary and processes pharmacy claims. When appealing, you may need to work with both CVS Caremark and your insurer.
First, request the denial reason in writing. Then file an internal appeal within the deadline in your denial letter (usually 180 days), including: documentation of why you need Zepbound specifically (e.g., a prior drug that didn't work), current BMI and comorbidity documentation, and a Letter of Medical Necessity from your doctor. Eli Lilly advises: "Don't give up! It is common to have to appeal more than once and you should be persistent in advocating for yourself." Free appeal templates are available at zepbound.lilly.com/access. If the internal appeal fails, you have the right to an external review by an independent organization, and the decision is binding.
If you exhaust your appeal options, consider: (1) LillyDirect Self Pay — Lilly's Self Pay Journey Program offers vials and KwikPens at $299–$449/month depending on dose; (2) Zepbound Savings Card — for commercially insured patients (terms expire December 31, 2026); (3) Ask about Wegovy — it's also preferred by CVS Caremark and works through a similar mechanism; (4) Foundayo — Eli Lilly's new obesity drug (FDA approved April 2026) may have different formulary status; (5) $200 copay plans — some CVS Caremark plans now offer a $200/month copay option where no coverage existed before; (6) Monitor the lawsuits — if the class action succeeds, coverage may be restored for affected patients.
WHAT'S COMING
CVS Caremark Coverage Outlook for 2026
Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize). From July 1, 2025 to September 30, 2026, Zepbound was nonpreferred or excluded on CVS Caremark’s most common commercial formularies, with Wegovy preferred. Employers and plans can customize their formulary, so some may still exclude Zepbound: check your own plan (CVS Health).
What Could Change Coverage
| Factor | Status | Potential Impact |
|---|---|---|
| Class Action Lawsuits | Pending (no rulings yet) | Settlement could restore coverage for affected patients |
| FTC PBM Lawsuit | Active against CVS, Express Scripts, OptumRx | Currently focused on insulin; could expand to GLP-1s[21] |
| PBM Reform Act of 2025 | Introduced (H.R. 4317) | Would ban spread pricing, increase transparency[22] |
| Employer Plan Changes | Ongoing | Self-funded employers can opt out of exclusions |
State-Level Changes to Watch
- California (CalPERS): Transitioned from OptumRx to CVS Caremark on January 1, 2026—state employees should verify new formulary status[23]
- Indiana: State employee plans now exclude all GLP-1s for weight loss (not just Zepbound) effective January 1, 2026[24]
- Wyoming: Launched new CVS Caremark weight management program with GLP-1 access via enrollment (January 2026)[25]
For Medicare policy updates, see our Medicare guide.
YOUR PATH FORWARD
What's Next
Zepbound Coverage: Other Major Insurers
Coverage depends on your insurance plan, not just your PBM. See insurer-specific guides:
- Aetna — Most plans exclude; limited employer exceptions with PA
- Blue Cross Blue Shield — Major 2026 coverage restrictions announced
- Cigna — Cigna plans may require step therapy; check your plan’s policy
- UnitedHealthcare — Coverage varies by plan; many require PA
- Humana — Humana no longer sells employer-group commercial medical plans (exit completed in 2025); Medicare drug plan members can use the Medicare GLP-1 Bridge
Other GLP-1 Medications at CVS Caremark
CVS Caremark's coverage varies by medication. Compare your options:
References
- CVS Caremark. (2025). "Enabling wider access to effective weight management treatment." business.caremark.com
- Pharmacy Times. (2025). "CVS Health Announces It Will Drop Zepbound and Prioritize Coverage of Wegovy." pharmacytimes.com
- CNN. (2025). "CVS Caremark stopped covering a GLP-1 for obesity. Now there's a lawsuit." cnn.com
- American Medical Association. (2024). "Over 80% of Prior Auth Appeals Succeed—Why Aren't There More?" ama-assn.org
- Obesity Action Coalition. (2025). "Appealing a Denied Prior Authorization." obesityaction.org
- Mass.gov. (2025). "CVS Caremark decides to remove Zepbound from CVS Caremark formulary." mass.gov
- KFF. (2024). "Medicare Advantage Insurers Made Nearly 50 Million Prior Authorization Determinations in 2023." kff.org
- Truveta. (2025). "Impact of the CVS GLP-1 formulary change: Trends in switching." truveta.com
- Claimable. (2025). "CVS Caremark denied Zepbound? Here's what to do if you don't want to switch to Wegovy." getclaimable.com
- KFF. (2024). "Medicare Advantage Insurers Made Nearly 50 Million Prior Authorization Determinations in 2023." kff.org
- KFF. (2024). "Claims Denials and Appeals in ACA Marketplace Plans in 2023." kff.org
- Pennsylvania Insurance Department. (2024). "Pennsylvania's Independent External Review Process Proves to be a Valuable Resource." pa.gov
- Berger Montague. (2025). "Larkin v. CVS Caremark - Class Action Lawsuit." bergermontague.com
- GoodRx. (2025). "Insurance Coverage for GIP and GLP-1 Agonists Like Zepbound." goodrx.com
- BioPharma Dive. (2025). "CVS strikes Wegovy deal with Novo Nordisk." biopharmadive.com
- Eli Lilly and Company. (2025). "Zepbound Access Resources." zepbound.lilly.com/access
- U.S. District Court, Southern District of New York. (2025). "Larkin v. CVS Caremark, LLC." Case No. 1:25-cv-07307. Filed September 3, 2025.
- Fierce Healthcare. (2025). "CVS Caremark faces class action after removing Zepbound from formularies." fiercehealthcare.com
- CVS Caremark. (2026). "Formulary strategies that deliver smart coverage and smarter savings." business.caremark.com
- Chain Drug Review. (2025). "CVS Caremark seeking a possible $200 copay for Wegovy and Zepbound." chaindrugreview.com
- Federal Trade Commission. (2025). "Pharmacy Benefits Managers (PBM) Lawsuit." ftc.gov
- U.S. Congress. (2025). "H.R.4317 - PBM Reform Act of 2025." congress.gov
- CalPERS. (2026). "Pharmacy Benefits: OptumRx Replaced by CVS Caremark." calpers.ca.gov
- Indiana State Personnel Department. (2025). "Open Enrollment: Prescription Coverage." in.gov
- Wyoming Administration & Information. (2025). "Weight Management & GLP-1." ai.wyo.gov
Last updated October 6, 2026 · Key facts verified October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.